Human nasal epithelium organ amplification culture medium and human primary nasal epithelium cell extraction and culture method

Through the extraction and culture method of human nasal epithelial organoid expansion medium and primary nasal epithelial cells, the model stability and aging problems in nasal epithelial organoid research were solved, and multiple passages and dry maintenance of nasal epithelial cells were achieved. , inhibits microbial growth, provides high-quality nasal epithelial cells and optimized culture conditions.

CN118995571APending Publication Date: 2024-11-22GUANG ZHOU YI XIN SHENG MING KE XUE YOU XIAN GONG SI
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202411116718.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-15
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The research on the intermediate nasal epithelial organoids in the prior art relies on traditional two-dimensional culture cell lines and animal models, lacks in vitro models that are stable and highly reducing real nasal epithelial tissue. The construction method of nasal epithelial organoids is relatively rare and prone to aging and mutation, and lacks Specialized nasal epithelial organoid culture medium formula and primary cell extraction methods.

Method used

Provide a method for extracting and culture of human nasal epithelial organoid amplification medium and primary nasal epithelial cells, using Advanced DMEM/F12 culture medium to combine various key components such as secretory activation proteins, fibroblast growth factors, antibiotics, etc. , through specific cleaning and digestive fluid treatment, ensure cell stemness and multiple passages, and preserve the culture medium under specific conditions to optimize the culture of nasal epithelial organoids.

Benefits of technology

Achieves multiple passages and cell stem maintenance of nasal epithelial organoids starting from primary cells, while inhibiting the growth of bacteria, fungi and other hybrid cells, providing high-quality nasal epithelial cells that support long-term survival and proliferation, and in Long-term preservation under specific conditions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118995571A_ABST
    Figure CN118995571A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of nasal epithelium organs, and discloses a human nasal epithelium organ amplification culture medium and an extraction and culture method of human primary nasal epithelial cells. The nasal epithelium organ amplification culture medium comprises multiple key components including R-spondin1 secretory activator protein, homodimer glycoprotein, FGF-7 and fibroblast growth factor 10, the culture medium is very important for proliferation, growth and dryness maintenance of nasal epithelial cells, and cell factors and synergists with specific concentrations can promote long-term survival and proliferation of cells, so that the culture medium has the advantages that the culture medium is suitable for large-scale popularization and application. Impurities are removed through the steps of centrifugation and filtration, cell passage and culture are carried out in a pretreated cell culture pore plate, an optimized culture medium formula not only supports long-term passage and proliferation of cells, but also can be stored for a long time at a specific temperature, and by optimizing culture of nasal epithelium organs, the culture efficiency of the cells is improved. The beneficial effects of realizing multiple passage of the nasal epithelium organ from the primary cell and maintaining the cell dryness of the nasal epithelium organ are achieved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of nasal epithelial organoids, and specifically to a human nasal epithelial organoid expansion culture medium and a method for extracting and culturing human primary nasal epithelial cells. Background Art

[0002] The nose is one of the five sense organs of the human body. The nose and nasal cavity play a very important role in human breathing, but they may also face many potential problems. On the one hand, the human respiratory tract, especially the nasopharyngeal epithelium, is the portal for respiratory viruses to enter and the main site of infection. The productive infection of SARS-CoV-2 in the nasal epithelium constitutes the cellular basis of the virus's pathogenesis and transmissibility. On the other hand, rhinitis such as chronic sinusitis is plaguing the daily lives of many people. These rhinitis may be multifactorial diseases associated with recurrent infections, which imposes a huge burden on the medical insurance system.

[0003] At present, the research on nasal epithelium still mainly relies on traditional two-dimensional cultured cell lines or animal models. These models have more or less some problems in terms of authenticity, stability, time and money costs, etc. A stable in vitro model of nasal epithelium that highly restores the real nasal epithelial tissue is still to be developed. Organoids are an emerging type of in vitro model construction method that can construct multicellular heterogeneous structures that highly simulate real tissues in vitro, greatly reducing various costs and avoiding problems such as homology. In the past, a large number of studies have shown that the use of progenitor cells from the epithelium of the airway, alveoli and other parts can be stably expanded and induced to form organoid cultures with specific structures and multiple cell types, and the construction of nasal epithelial organoids has also been studied to a certain extent.

[0004] However, compared to the airways and alveoli, relevant research reports on nasal epithelial organoids are still relatively rare. On the one hand, the progenitor cells are extracted from the patient's resected tissue and induced to form nasal epithelial organoids through proliferation and differentiation. The organoids obtained by this method may have some pathological characteristics of the patients and cannot completely simulate normal nasal epithelial tissue. On the other hand, most of the current nasal epithelial organoids are directly cultured using organoid culture media from similar parts such as airway epithelium. There is a lack of special optimization for the culture of nasal epithelial organoids, which can easily lead to aging and mutation of organoids after multiple passages. Therefore, current research on nasal epithelial organoids still requires a culture medium formula specifically configured for the proliferation of nasal epithelial organoids, as well as a more general method for extracting and culturing primary nasal epithelial cells. Summary of the invention

[0005] 1. Technical issues to be resolved

[0006] In view of the deficiencies of the prior art, the present invention provides a human nasal epithelial organoid expansion culture medium and a method for extracting and culturing human primary nasal epithelial cells, which have the advantages of realizing multiple passaging of nasal epithelial organoids from primary cells and maintaining their cell stemness, while inhibiting the growth of bacteria, fungi and other miscellaneous cells, thereby solving the problems of the above-mentioned technologies.

[0007] (II) Technical solution

[0008] To achieve the above-mentioned purpose, the present invention provides a technical solution: the culture medium consists of a basal culture medium, 4-hydroxyethylpiperazineethanesulfonic acid, glutamine, penicillin-streptomycin, R-spondin 1, noggin, B27 serum-free additive, N-acetyl-L-cysteine, nicotinamide, Y-27632 dihydrochloride, ALK5 inhibitor, SB202190 hydrochloride, fibroblast growth factor 7, fibroblast growth factor 10 and primary cell antibiotics.

[0009] Preferably, the composition of the nasal epithelial organoid expansion medium in the method is:

[0010] Advanced DMEM / F12;

[0011] 4-20μM / L / LHEPES hepatosulfonic acid;

[0012] 1.5-3mM / L / L GlutaMAX alanyl-glutamine;

[0013] 80-150 units / mL penicillin-streptomycin;

[0014] 20-110 ng / mL secretory activator protein;

[0015] 4-20 ng / mL homodimeric glycoprotein;

[0016] 0.8-1.3 ng / mL B27 supplement;

[0017] 1-1.5mM / L / L N-acetylcysteine;

[0018] 7-12mM / L / L nicotinamide;

[0019] 3-8μM / L / LRHO-related protein kinase inhibitor;

[0020] 250-700nM / L small molecule inhibitors;

[0021] 0.7-1.2μM / L / L cell-permeable P38 MAPK inhibitor;

[0022] 3-7 ng / mL fibroblast growth factor 7;

[0023] 16-25 ng / mL fibroblast growth factor 10;

[0024] 50-120 μg / mL primary cell antibiotics;

[0025] 0-8nM / L polypeptide molecule.

[0026] Preferably, the composition of the primary nasal epithelial cell washing solution in the method is:

[0027] Advanced DMEM / F12;

[0028] 1.5-3mM / L / L GlutaMAX alanyl-glutamine;

[0029] 80-150 units / mL penicillin-streptomycin;

[0030] 50-120μg / mL antibiotics for primary cells.

[0031] Preferably, the composition of the primary nasal epithelial digestive fluid in the method is:

[0032] TrypLE Express;

[0033] 7-15mg / mL Sputolysin.

[0034] Preferably, the basal medium is Advanced DMEM / F12 medium, wherein the mixing ratio of DMEM to Ham's F-12 is 1:1, the concentration of 4-hydroxyethylpiperazineethanesulfonic acid is 4-20 μM, the concentration of glutamine is 1.5-3 mM, the concentration of penicillin in penicillin-streptomycin is 80-150 units / mL, the concentration of streptomycin is 80-150 units / mL, the concentration of R-spondin 1 is 20-110 ng / mL, the concentration of noggin is 4-20 ng / mL, the concentration of B27 serum-free additive is 0.8-1.3 ng / mL, and the concentration of N-acetylcholine is 1.5-20 ng / mL. -L-cysteine ​​1-1.5mM, the nicotinamide concentration is 7-12mM, the Y-27632 dihydrochloride concentration is 3-8μM, the ALK5 inhibitor concentration is 250-700nM, the SB202190 hydrochloride concentration is 0.7-1.2μM, the fibroblast growth factor 7 concentration is 3-7ng / mL, the fibroblast growth factor 10 concentration is 16-25ng / mL, and the primary cell antibiotic concentration is 50-120μg / mL.

[0035] Preferably, after the configuration is completed, the nasal epithelial organoid expansion medium can be stored at -30 to -15°C for 2 to 8 months, and at 2°C to 8°C for 1 to 8 weeks.

[0036] A method for extracting primary human nasal epithelial cells, the method comprising:

[0037] Step 1: Use a nasal swab to extract from the subject's nasal cavity and collect cells in primary nasal epithelial cell washing solution;

[0038] Step 2: Use primary nasal epithelial digestion solution to digest and disperse the collected cells, use a cell filter to remove non-cellular impurities, and resuspend the collected cells in human nasal epithelial organoid expansion medium.

[0039] Preferably, in step one, a nasal swab is used to scrape the nasal turbinate of the subject's nasal cavity to extract nasal epithelial cells. The use of the nasal swab to extract nasal epithelial cells requires the nasal swab to be rotated 4-30 times in a fixed position to fully collect the cells.

[0040] Preferably, the primary nasal epithelial cell washing solution in step 1 comprises the basal culture medium Advanced DMEM / F12 and GlutaMAX alanyl-glutamine at a concentration of 1.5-3 mM / L / L, penicillin-streptomycin at a concentration of 80-150 units / mL, and primary cell antibiotics at a concentration of 50-120 μg / mL.

[0041] Preferably, in step one, the cells are collected by scraping the nasal swab 5-20 times in the cell washing solution using a 1 mL or 1.25 mL pipette tip with 4-12 mm of the tip cut off, or by vortexing the nasal swab in the cell washing solution on a vortex oscillator for 20-60 seconds to collect the cells. After the cells are collected in step one, they are centrifuged at a temperature of 4-25° C., a centrifugal force of 200-600 g, and a time of 2-8 min, and the cell washing solution is discarded.

[0042] Preferably, the primary nasal epithelial digestion solution in step 2 comprises a basic digestion solution TrypLE Express and Sputolysin at a concentration of 7-15 mg / mL. In step 2, 2-10 mL of nasal epithelial digestion solution is used for digestion at 37°C for 5-30 min, and then 4-25 mL of nasal epithelial organoid expansion medium or PBS is used to terminate the digestion. In step 2, a cell filter with a pore size of 70-100 μm is used for filtration. After filtration, 1-5 mL of nasal epithelial organoid expansion medium or PBS is used to wash the filter, and all filtrate is collected. After filtration in step 2, the temperature is 4-25°C, the centrifugal force is 200-600g, and the time is 2-8 min. The terminated digestion solution is discarded to collect the cells. After collecting the cells in step 2, 50-200 μL of nasal epithelial organoid expansion medium is used to resuspend the cells, and the cells are counted, with a final number of 2-10×10 5Dilute the cell suspension in Nasal Epithelial Organoid Expansion Medium at a cell density of 10 cells / mL.

[0043] A method for culturing primary human nasal epithelial cells comprises: using a well plate pretreatment solution to pretreat a well plate for cell culture to be used, and adding a cell suspension into the pretreated well plate for culturing.

[0044] Preferably, the well plate pretreatment solution contains 20-500 μg / mL type I collagen or type IV collagen solution, the well plate to be used for cell culture is pretreated with the well plate pretreatment solution for 1-24 hours, then the well plate pretreatment solution is discarded, the treated culture well plate is cleaned with PBS, the bottom of the well plate is immersed in PBS until the PBS is discarded before inoculating cells, the diluted cell suspension is added to the pretreated cell culture well plate, the well plate is placed in a carbon dioxide cell culture incubator for culture, the culture temperature is 35-38°C, the CO2 concentration is 4-6%, the culture humidity is 92-98%, and the cell culture medium is updated every 1-4 days for the cultured cells.

[0045] Compared with the prior art, the present invention provides a human nasal epithelial organoid expansion medium and a method for extracting and culturing human primary nasal epithelial cells, which have the following beneficial effects:

[0046] 1. The nasal epithelial organoid expansion culture medium of the present invention comprises a variety of key components, such as secretory activator protein, homodimeric glycoprotein, fibroblast growth factor 7, and fibroblast growth factor 10, which are very important for the proliferation, growth and maintenance of stemness of nasal epithelial cells. Specific concentrations of cytokines and enhancers can promote the long-term survival and proliferation of cells. Primary nasal epithelial cells are extracted from the nasal cavity of the subject with a nasal swab, and specific cleaning and digestion solutions are used to process and separate the cells, ensuring that high-quality primary cells are obtained from the beginning, and impurities are removed by centrifugation and filtration steps. Cells are passaged and cultured in pretreated cell culture well plates. The preferred culture medium formula not only supports long-term cell passage and proliferation, but also can be stored for a long time at a specific temperature. By optimizing it specifically for the culture of nasal epithelial organoids, the beneficial effects of achieving multiple passages of nasal epithelial organoids from primary cells and maintaining their cell stemness are achieved.

[0047] 2. The present invention can effectively inhibit the growth of bacteria, including most Gram-positive and Gram-negative bacteria, by adding penicillin-streptomycin and primary cell antibiotics to the nasal epithelial organoid expansion culture medium. The primary cell antibiotics can inhibit the growth of Gram-positive bacteria and fungi, thereby helping to maintain the sterility of the culture. N-acetylcysteine, antioxidants and mucolytics are also added to the culture medium, which are also effective in inhibiting fungal growth. In the process of extracting and processing primary nasal epithelial cells, aseptic operation techniques and culture media are used to ensure that bacterial and fungal contamination is reduced from the beginning. The collected cells are filtered using a cell filter to remove non-cellular impurities, further reducing microbial contamination in the culture. The culture conditions, including the temperature, humidity and CO2 concentration in the incubator, are strictly controlled to provide an environment most suitable for cell growth and inhibition of microbial growth, thereby achieving the beneficial effect of simultaneously inhibiting the growth of bacteria, fungi and other miscellaneous cells. BRIEF DESCRIPTION OF THE DRAWINGS

[0048] Figure 1 Schematic diagram of screening and amplification of primary nasal epithelial progenitor cells of the present invention;

[0049] Figure 2 A schematic diagram of the effect of the present invention on the expansion and construction of a single-layer nasal epithelial organoid in a two-dimensional environment;

[0050] Figure 3 A schematic diagram of the effect of the present invention on the expansion and construction of nasal epithelial organoids in a three-dimensional environment;

[0051] Figure 4 This is a schematic diagram of the effect of the subsequent induction of differentiation of nasal epithelial organoids by the present invention, wherein the left one is a two-dimensional environment, and the right one is a three-dimensional environment, wherein green represents goblet cells and red represents the ciliary structure of ciliated cells, and both cells are the main functional cells of the nasal epithelium;

[0052] Figure 5 This is a schematic diagram of the tight junction physical barrier formed by the subsequent induced differentiation of a single layer of nasal epithelial organoids in a two-dimensional environment in the present invention, wherein the left one is before differentiation and the right one is after differentiation. DETAILED DESCRIPTION

[0053] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0054] See also Figure 1, Advanced DMEM / F12, HEPES-HEPES, GlutaMAX alanyl-glutamine, penicillin-streptomycin, B27 supplement, and TrypLE Express were purchased from Gibco;

[0055] Rspondin1, homodimeric glycoprotein, N-acetylcysteine, nicotinamide, RHO-related protein kinase inhibitor, small molecule inhibitor, and cell-permeable P38 MAPK inhibitor were purchased from GlpBio;

[0056] Fibroblast growth factor 7, fibroblast growth factor 10, and polypeptide molecules were purchased from SinoBiological;

[0057] Antibiotics for primary cells were purchased from InvivoGen;

[0058] Sputolysin was purchased from Sigma;

[0059] Type I collagen and type IV collagen were purchased from Corning.

[0060] Embodiment 1:

[0061] The nasal epithelial organoid expansion medium contains the basic medium Advanced DMEM / F12 and 4μM / L / L HEPES sea sulfonic acid, 1.5mM / L / L GlutaMAX alanine glutamine, 80 units / mL penicillin-streptomycin, 20ng / mL secretory activator protein, 4ng / mL homodimeric glycoprotein, 0.8ng / mL B27 supplement, 1mM / L / L N-acetylcysteine, 7mM / L / L nicotinamide, 3μM / L / L RHO-related protein kinase inhibitor, 250nM / L small molecule inhibitor, 0.7μM / L / L cell permeable P38 MAPK inhibitor, 3ng / mL fibroblast growth factor 7, 16ng / mL fibroblast growth factor 10, 50μg / mL primary cell antibiotics and 0nM / L peptide molecules. After preparation, the culture medium can be stored at -30°C for 8 months and at 2°C for 8 weeks during use.

[0062] Human primary nasal epithelial cell extraction method: A nasal swab was rotated 4 times at a fixed position at the nasal concha of the subject's nasal cavity to extract nasal epithelial cells. The cells were collected by rubbing the nasal swab 5 times in the cell washing solution containing Advanced DMEM / F12 and 1.5mM / L / LGlutaMAX alanyl-glutamine, 80 units / mL penicillin-streptomycin, and 50μg / mL primary cell antibiotics using a 1mL pipette tip with 4mm of the tip cut off. The temperature was 4°C, the centrifugal force was 200g, and the time was 8min. Centrifugation was performed and the cell washing solution was discarded;

[0063] Use 2 mL of nasal epithelial digestion solution containing TrypLE Express and 7 mg / mL Sputolysin to digest and disperse the cells at 37°C for 5 min, then use 4 mL of nasal epithelial organoid expansion medium to terminate the digestion, filter using a cell strainer with a pore size of 70 μm, and use 1 mL of nasal epithelial organoid expansion medium to wash the filter after filtration. Collect all the filtrate to remove non-cellular impurities, centrifuge at 4°C, 200 g, and time for 8 min, discard the terminated digestion solution to collect the cells, resuspend the cells in 50 μL of nasal epithelial organoid expansion medium, and count the cells to a final count of 2×10 5 Dilute the cell suspension with nasal epithelial organoid expansion medium at a cell density of 100 / mL;

[0064] The cell culture well plate to be used was pretreated with a well plate pretreatment solution containing 20 μg / mL type I collagen for 1 hour, and then the well plate pretreatment solution was discarded. The treated culture well plate was washed with PBS, and the bottom of the well plate was immersed in PBS until the PBS was discarded before inoculating cells. The diluted cell suspension was added to the pretreated cell culture well plate, and the well plate was placed in a carbon dioxide cell culture incubator for culture at a temperature of 35°C, a CO2 concentration of 4%, and a culture humidity of 92%. The cell culture medium was renewed every 1 day.

[0065] Schematic diagram of screening and expansion of primary nasal epithelial progenitor cells Figure 1 As shown. After 7 days of primary culture, the cells were observed under an inverted microscope and showed cobblestone growth. The morphology of adherent cells was uniform. Cell counting results showed that primary cells proliferated significantly within 5-7 days and the cell viability was good.

[0066] Example 2

[0067] Please refer to the instruction manual Figure 2The nasal epithelial organoid expansion medium contains the basic medium Advanced DMEM / F12 and 9μM / L / L HEPES sea sulfonic acid, 1.7mM / L / L GlutaMAX alanine glutamine, 100 units / mL penicillin-streptomycin, 50ng / mL secretory activator protein, 7ng / mL homodimeric glycoprotein, 0.9ng / mL B27 supplement, 1.15mM / L / L N-acetylcysteine, 8.4mM / L / L nicotinamide, 4μM / L / L RHO-related protein kinase inhibitor, 290nM / L small molecule inhibitor, 0.8μM / L / L cell permeable P38 MAPK inhibitor, 4.2ng / mL fibroblast growth factor 7, 18ng / mL fibroblast growth factor 10, 65μg / mL primary cell antibiotics and 2nM / L peptide molecules. After preparation, the culture medium can be stored at -25°C for 6 months and at 3°C ​​for 7 weeks during use.

[0068] Human primary nasal epithelial cell extraction method: A nasal swab was rotated 6 times at a fixed position at the nasal concha of the subject's nasal cavity to extract nasal epithelial cells. The cells were collected by rubbing the nasal swab 15 times in the primary nasal epithelial cell washing solution containing Advanced DMEM / F12 and 1.7mM / L / LGlutaMAX alanyl-glutamine, 100 units / mL penicillin-streptomycin, and 65μg / mL primary cell antibiotics using a 1.25mL pipette tip with 6mm of the tip cut off in the cell washing solution. The temperature was 10°C, the centrifugal force was 250g, and the time was 6min. Centrifugation was performed and the cell washing solution was discarded;

[0069] Use 4 mL of nasal epithelial digestion solution containing TrypLE Express and 8.5 mg / mL Sputolysin to digest and disperse the cells at 37°C for 8 minutes, then use 6 mL of PBS to terminate the digestion, filter using a cell strainer with a pore size of 70 μm, wash the strainer with 2 mL of PBS after filtration, collect all the filtrate to remove non-cellular impurities, centrifuge at 10°C, centrifugal force 250g, and time 6 minutes, discard the terminated digestion solution to collect the cells, resuspend the cells in 80 μL of nasal epithelial organoid expansion medium, count the cells, and dilute the cell suspension with nasal epithelial organoid expansion medium to a final cell density of 4×105 cells / mL;

[0070] The cell culture well plate to be used was pretreated with a well plate pretreatment solution containing 50 μg / mL type IV collagen for 2 hours, then the well plate pretreatment solution was discarded, the treated culture well plate was washed with PBS, the bottom of the well plate was immersed in PBS until the PBS was discarded before inoculating cells, the diluted cell suspension was added to the pretreated cell culture well plate, and the well plate was placed in a carbon dioxide cell culture incubator for culture at a temperature of 36°C, a CO2 concentration of 4.5%, a culture humidity of 93%, and the cell culture medium was renewed every 2 days.

[0071] Schematic diagram of the effect of primary nasal epithelial progenitor cells expanding in a two-dimensional environment to construct a single-layer nasal epithelial organoid Figure 2 As shown. Using an inverted microscope, cells at different stages of constructing a monolayer of nasal epithelial organoids were observed, and the conditions were all relatively good. In the late differentiation stage, the cells were observed to be tightly arranged polygonal cells with clear cell boundaries, high cell density and good cell layer coverage. The cell layer was intact without gaps or damage, and cilia were observed to exist and sway regularly under the microscope.

[0072] Embodiment 3:

[0073] Please refer to the instruction manual Figure 3 The nasal epithelial organoid expansion medium contains the basal medium Advanced DMEM / F12 and 12μM / L / L HEPES sea sulfonic acid, 2mM / L / L GlutaMAX alanyl-glutamine, 110 units / mL penicillin-streptomycin, 75ng / mL secretory activator protein, 9.5ng / mL homodimeric glycoprotein, 1ng / mL B27 supplement, 1.2mM / L / L N-acetylcysteine, 9.5mM / L / L nicotinamide, 5.5μM / L / L RHO-related protein kinase inhibitor, 350nM / L small molecule inhibitor, 0.9μM / L / L cell permeable P38 MAPK inhibitor, 4.5ng / mL fibroblast growth factor 7, 20ng / mL fibroblast growth factor 10, 72μg / mL primary cell antibiotics and 3.5nM / L peptide molecules. The culture medium can be stored at -20°C for 4 months after preparation and at 4°C for 7 weeks during use;

[0074] Human primary nasal epithelial cell extraction method: A nasal swab was rotated 10 times at a fixed position at the nasal concha of the subject's nasal cavity to extract nasal epithelial cells. The nasal swab was vortexed for 20 seconds in a primary nasal epithelial cell washing solution containing Advanced DMEM / F12 and 2mM / L / LGlutaMAX alanyl-glutamine, 110 units / mL penicillin-streptomycin, and 72μg / mL primary cell antibiotics to collect cells. The temperature was 15°C, the centrifugal force was 300g, and the time was centrifuged for 5 minutes, and the cell washing solution was discarded;

[0075] Use 6 mL of nasal epithelial digestion solution containing TrypLE Express and 10 mg / mL Sputolysin at 37°C for 12 min to digest and disperse the cells, then use 12 mL of PBS to terminate the digestion, filter using a cell strainer with a pore size of 100 μm, and wash the strainer with 4 mL of PBS after filtration. Collect all the filtrate to remove non-cellular impurities, centrifuge at 15°C, 300 g, and time for 5 min, discard the terminated digestion solution to collect the cells, resuspend the cells in 100 μL of nasal epithelial organoid expansion medium, and count the cells to a final number of 5×10 5 Dilute the cell suspension with nasal epithelial organoid expansion medium at a cell density of 100 / mL;

[0076] The cell culture well plates to be used were pretreated with a well plate pretreatment solution containing 100 μg / mL type I collagen for 5 h, then the well plate pretreatment solution was discarded, the treated culture well plates were washed with PBS, the bottom of the well plates were immersed in PBS until the PBS was discarded before inoculating cells, the diluted cell suspension was added to the pretreated cell culture well plates, and the well plates were placed in a carbon dioxide cell culture incubator for culture at a temperature of 37°C, a CO2 concentration of 5%, a culture humidity of 95%, and the cell culture medium was renewed every 3 days.

[0077] Schematic diagram of the effect of primary nasal epithelial progenitor cells expanding in a three-dimensional environment to construct nasal epithelial organoids. Figure 3 As shown. Using an inverted microscope to observe the state of nasal epithelial organoids in a three-dimensional environment, it can be seen that the nasal epithelial organoids are spheres of uniform size, and the cells are evenly distributed inside the organoids. The organoids have appropriate density, healthy morphology, and clear edges. Cilia can be observed on the surface of the organoids and they swing regularly under the microscope.

[0078] Example 4

[0079] Please refer to the instruction manual Figure 4The nasal epithelial organoid expansion medium contains the basic medium Advanced DMEM / F12 and 15μM / L / L HEPES sea sulfonic acid, 2.5mM / L / L GlutaMAX alanyl-glutamine, 120 units / mL penicillin-streptomycin, 90ng / mL secretory activator protein, 15ng / mL homodimeric glycoprotein, 1.2ng / mL B27 supplement, 1.3mM / L / L N-acetylcysteine, 10mM / L / L nicotinamide, 6μM / L / L RHO-related protein kinase inhibitor, 500nM / L small molecule inhibitor, 1μM / L / L cell permeable P38 MAPK inhibitor, 6ng / mL fibroblast growth factor 7, 22ng / mL fibroblast growth factor 10, 100μg / mL primary cell antibiotics and 5nM / L peptide molecules. After the preparation is completed, the culture medium can be stored at -20°C for 4 months and at 6°C for 3 weeks during use.

[0080] Human primary nasal epithelial cell extraction method: A nasal swab was rotated 20 times at a fixed position at the nasal concha of the subject's nasal cavity to extract nasal epithelial cells. The nasal swab in the cell washing solution containing Advanced DMEM / F12 and 2.5mM / L / LGlutaMAX alanyl-glutamine, 120 units / mL penicillin-streptomycin, and 100μg / mL primary cell antibiotics was vortexed by using a vortex oscillator for 40s to collect cells, and the temperature was 20°C, the centrifugal force was 400g, and the time was centrifuged for 3min, and the cell washing solution was discarded;

[0081] 8 mL of nasal epithelial digestion solution containing TrypLE Express and 12 mg / mL Sputolysin was used to digest and disperse the cells at 37°C for 20 min, and then 16 mL of PBS was used to terminate the digestion. The cells were filtered using a cell strainer with a pore size of 100 μm. After filtration, the strainer was washed with 5 mL of PBS, and all the filtrate was collected to remove non-cellular impurities. The cells were centrifuged at 20°C, 400 g, and 3 min. The digestion solution after termination was discarded to collect the cells, and the cells were resuspended in 150 μL of nasal epithelial organoid expansion medium. The cells were counted, with a final number of 8 × 10 5 Dilute the cell suspension with nasal epithelial organoid expansion medium at a cell density of 100 / mL;

[0082] The cell culture well plate to be used was pretreated with a well plate pretreatment solution containing 250 μg / mL type I collagen for 12 h, and then the well plate pretreatment solution was discarded. The treated culture well plate was washed with PBS, and the bottom of the well plate was immersed in PBS until the PBS was discarded before inoculating cells. The diluted cell suspension was added to the pretreated cell culture well plate, and the well plate was placed in a carbon dioxide cell culture incubator for culture at a temperature of 37°C and CO 2 The concentration was 5%, the culture humidity was 95%, and the cell culture medium was renewed every 3 days.

[0083] Schematic diagram of the effect of inducing differentiation of nasal epithelial organoids constructed by expansion of primary nasal epithelial progenitor cells. Figure 4 As shown, the left one is a two-dimensional environment, and the right one is a three-dimensional environment; green represents goblet cells and red represents the ciliary structure of ciliated cells. These two cells are the main functional cells of the nasal epithelium. The results showed that the entire organoid was stained evenly, and there were no areas with strong or weak staining. The nucleus staining with DAPI showed that the boundary between the nucleus and the cytoplasm was clearly visible. The obvious clustered ciliary structure can be seen in the figure, indicating that the nasal epithelial organoids were successfully induced to differentiate.

[0084] Example 5

[0085] Please refer to the instruction manual Figure 5 The nasal epithelial organoid expansion medium contains the basic medium Advanced DMEM / F12 and 20μM 4-hydroxyethylpiperazineethanesulfonic acid, 3mM glutamine, 150 units / mL penicillin-streptomycin, 110ng / mL R-spondin 1, 20ng / mL noggin, 1.3ng / mL B27 serum-free supplement, 1.5mM N-acetyl-L-cysteine, 12mM nicotinamide, 8μM Y-27632 dihydrochloride, 700nM ALK5 inhibitor, 1.2μM SB202190 hydrochloride, 7ng / mL fibroblast growth factor 7, 25ng / mL fibroblast growth factor 10 and 120μg / mL primary cell antibiotics. After preparation, the medium can be stored at -15°C for 2 months and at 8°C for 1 week during use.

[0086] Human primary nasal epithelial cell extraction method: A nasal swab was rotated 30 times at a fixed position at the nasal concha of the subject's nasal cavity to extract nasal epithelial cells. The cells were collected by rubbing the nasal swab 20 times in the cell washing solution containing Advanced DMEM / F12 and 3mM / L / LGlutaMAX alanyl-glutamine, 150 units / mL penicillin-streptomycin, and 120μg / mL primary cell antibiotics using a 1.25mL pipette tip with 12mm of the tip cut off. The temperature was 25°C, the centrifugal force was 600g, and the time was centrifuged for 2min, and the cell washing solution was discarded;

[0087] The cells were digested and dispersed using 10 mL of nasal epithelial digestion solution containing TrypLE Express and 15 mg / mL Sputolysin at 37°C for 30 min, and then digested and dispersed using 25 mL of PBS. The cells were filtered using a cell strainer with a pore size of 70 μm. After filtration, the strainer was washed with 5 mL of PBS, and all the filtrate was collected to remove non-cellular impurities. The cells were centrifuged at 25°C, 600 g, and 2 min. The digestion solution after termination was discarded to collect the cells, and the cells were resuspended in 200 μL of nasal epithelial organoid expansion medium. The cells were counted and the final number was 10 × 10 5 Dilute the cell suspension with nasal epithelial organoid expansion medium at a cell density of 100 / mL;

[0088] The cell culture well plates to be used were pretreated with a well plate pretreatment solution containing 500 μg / mL type IV collagen for 24 h, then the well plate pretreatment solution was discarded, the treated culture well plates were washed with PBS, the bottom of the well plates were immersed in PBS until the PBS was discarded before inoculating cells, the diluted cell suspension was added to the pretreated cell culture well plates, and the well plates were placed in a carbon dioxide cell culture incubator for culture at a temperature of 38°C, a CO2 concentration of 6%, a culture humidity of 98%, and the cell culture medium was renewed every 4 days.

[0089] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.

Claims

1. A human nasal epithelial organoid expansion culture medium, characterized in that The culture medium consists of basal medium, 4-hydroxyethylpiperazineethanesulfonic acid, glutamine, penicillin-streptomycin, R-spondin 1, noggin, B27 serum-free supplement, N-acetyl-L-cysteine, nicotinamide, Y-27632 dihydrochloride, ALK5 inhibitor, SB202190 hydrochloride, fibroblast growth factor 7, fibroblast growth factor 10 and primary cell antibiotics.

2. A human nasal epithelial organoid expansion medium according to claim 1, characterized in that: The basic culture medium is Advanced DMEM / F12 culture medium, wherein the mixing ratio of DMEM to Ham's F-12 is 1:1 by volume, the concentration of 4-hydroxyethylpiperazineethanesulfonic acid is 4-20 μM, the concentration of glutamine is 1.5-3 mM, the concentration of penicillin in penicillin-streptomycin is 80-150 units / mL, the concentration of streptomycin is 80-150 units / mL, the concentration of R-spondin 1 is 20-110 ng / mL, the concentration of noggin is 4-20 ng / mL, the concentration of B27 serum-free additive is 0.8-1.3 ng / mL, and the concentration of N-acetylcholine is 1.5-20 ng / mL. -The concentration of L-cysteine ​​is 1-1.5mM, the concentration of nicotinamide is 7-12mM, the concentration of Y-27632 dihydrochloride is 3-8μM, the concentration of ALK5 inhibitor is 250-700nM, the concentration of SB202190 hydrochloride is 0.7-1.2μM, the concentration of fibroblast growth factor 7 is 3-7ng / mL, the concentration of fibroblast growth factor 10 is 16-25ng / mL, and the concentration of primary cell antibiotic is 50-120μg / mL.

3. A method for extracting primary human nasal epithelial cells, characterized in that: The extraction method comprises the following steps: Step 1: Use a nasal swab to extract from the subject's nasal cavity and collect cells in primary nasal epithelial cell washing solution; Step 2: Use primary nasal epithelial digestion fluid to digest and disperse the collected cells, use a cell filter to remove non-cellular impurities, and after collecting the cells, resuspend them using the human nasal epithelial organoid expansion medium described in claim 1.

4. The method for extracting primary human nasal epithelial cells according to claim 3, characterized in that: In step one, a nasal swab is used to scrape the nasal turbinate of the subject's nasal cavity to extract nasal epithelial cells. The use of the nasal swab to extract nasal epithelial cells requires the nasal swab to be rotated 4-30 times in a fixed position to fully collect the cells.

5. The method for extracting primary human nasal epithelial cells according to claim 3, characterized in that: The primary nasal epithelial cell washing solution described in step 1 contains the basic culture medium Advanced DMEM / F12 and GlutaMAX alanyl-glutamine at a concentration of 1.5-3mM / L / L, penicillin-streptomycin at a concentration of 80-150 units / mL, and primary cell antibiotics at a concentration of 50-120μg / mL.

6. The method for extracting primary human nasal epithelial cells according to claim 3, characterized in that: In the step 1, the cells are collected by scraping the nasal swab 5-20 times in the cell washing solution using a 1 mL or 1.25 mL pipette tip with 4-12 mm of the tip cut off, or by vortexing the nasal swab in the cell washing solution on a vortex oscillator for 20-60 seconds. After the cells are collected in the step 1, they are centrifuged at a temperature of 4-25° C., a centrifugal force of 200-600 g, and a time of 2-8 minutes, and the cell washing solution is discarded.

7. The method for extracting primary human nasal epithelial cells according to claim 3, characterized in that: The primary nasal epithelial digestion solution described in step 2 comprises a basic digestion solution TrypLE Express and a 7-15 mg / mL concentration of Sputolysin. In step 2, 2-10 mL of nasal epithelial digestion solution is used for digestion at 37° C. for 5-30 min, and then 4-25 mL of nasal epithelial organoid expansion medium or PBS is used to terminate the digestion. In step 2, a cell filter with a pore size of 70-100 μm is used for filtration. After filtration, 1-5 mL of nasal epithelial organoid expansion medium or PBS is used to wash the filter, and all filtrate is collected. After filtration in step 2, the temperature is 4-25° C., the centrifugal force is 200-600 g, and the time is 2-8 min. The terminated digestion solution is discarded to collect the cells. After collecting the cells in step 2, 50-200 μL of nasal epithelial organoid expansion medium is used to resuspend the cells, and the cells are counted, with a final number of 2-10×10 5 Dilute the cell suspension in Nasal Epithelial Organoid Expansion Medium at a cell density of 10 cells / mL.

8. A method for culturing primary human nasal epithelial cells, characterized in that: The culture method comprises: using a well plate pretreatment solution to pretreat the well plate to be used for cell culture, and adding the cell suspension into the pretreated well plate for culture.

9. The method for culturing primary human nasal epithelial cells according to claim 8, characterized in that: The well plate pretreatment solution contains 20-500 μg / mL type I collagen or type IV collagen solution; the well plate pretreatment solution is used to pretreat the cell culture well plate to be used for 1-24 hours, then the well plate pretreatment solution is discarded, the treated culture well plate is cleaned with PBS, the bottom of the well plate is immersed in PBS until the PBS is discarded before inoculating cells, the diluted cell suspension is added to the pretreated cell culture well plate, the well plate is placed in a carbon dioxide cell culture incubator for culture, the culture temperature is 35-38°C, the CO2 concentration is 4-6%, the culture humidity is 92-98%, and the cell culture medium is renewed every 1-4 days for the cultured cells.

Citation Information

Cited By

  • IPS-driven nasopharyngeal epithelium organ as well as preparation method and application thereof

    CN119639656A

  • Microfluidic chip for dynamic culture of nasal epithelium organs and culture method thereof

    CN119709402A